Yonemori K, Boni V, Min KG, Meniawy TM, et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study. Gynecol Oncol 2024;191:172-181.
PMID: 39442371